CAJ | 학술논문

肿瘤坏死因子相关凋亡配体受体（ TRAIL-R）是TRAIL介导细胞凋亡的重要结合靶点，其中TRAIL-R1和TRAIL-R2（即死亡受体4和死亡受体5）是与诱导细胞凋亡最直接相关的受体，也是最具有开发前景的药物设计靶点。本文对TRAIL-R及其抗体的临床前和临床研究作全面综述，为探索TRAIL介导的抗肿瘤治疗进一步研究提供参考。
종류배사인자상관조망배체수체（ TRAIL-R）시TRAIL개도세포조망적중요결합파점，기중TRAIL-R1화TRAIL-R2（즉사망수체4화사망수체5）시여유도세포조망최직접상관적수체，야시최구유개발전경적약물설계파점。본문대TRAIL-R급기항체적림상전화림상연구작전면종술，위탐색TRAIL개도적항종류치료진일보연구제공삼고。
Tumor necrosis factor-related apoptosis-inducing ligand receptor(TRAIL-R), one of important binding targets of TRAIL-mediated apoptosis, including TRAIL-R1 and TRAIL-R2( ie, death receptor 4 and death receptor 5) not only directly relates to the induction of apoptosis receptors, but also one of the most promising targets for drug design. We carried out a comprehensive review of these antibodies?preclinical and clinical studies to explore the TRAIL-mediated anti-tumor therapy and provide references for further study.